Welcome to our dedicated page for Neurogene SEC filings (Ticker: NGNE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Neurogene Inc. (NGNE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage gene therapy company, Neurogene uses current reports on Form 8-K and other filings to communicate material events related to its Rett syndrome program NGN-401, financial results and corporate presentations.
Recent 8-K filings reference press releases announcing quarterly financial results, including research and development and general and administrative expenses, as well as updates on cash resources. Other 8-Ks furnish clinical and regulatory milestones, such as positive interim data from the NGN-401 Phase 1/2 trial, dosing of the first participant in the Embolden registrational trial, completion of discussions with the FDA on the Embolden protocol, and related corporate presentations made available on the company’s website.
For users analyzing NGNE, these filings help clarify how Neurogene reports its progress in Rett syndrome, the structure and status of the Embolden trial, and key financial metrics associated with its development-stage operations. Forms 8-K also document the timing and content of public communications, including clinical data updates and preclinical findings on intracerebroventricular versus intrathecal lumbar delivery of NGN-401.
On Stock Titan, SEC documents are paired with AI-powered summaries that highlight the main points of lengthy filings, allowing readers to quickly understand the nature of each disclosure. Investors can use this page to monitor new 8-Ks and other SEC reports for NGNE, track clinical and regulatory developments, and review how Neurogene describes risks, forward-looking statements and financial condition in its official filings.
Neurogene Inc. submitted an initial insider ownership report on Form 3 for Christina Shafer, who serves as the company’s Chief Commercial Officer. The filing does not list any equity transactions or derivative positions, and the transaction summary shows zero buy, sell, or exercise activity.
Neurogene Inc. expanded its Board of Directors to seven members and appointed its President and Chief Financial Officer, Christine Mikail, J.D., as a Class II director whose term runs until the 2028 annual stockholder meeting.
The company also appointed Christy Shafer as Chief Commercial Officer to lead commercial strategy and launch readiness for NGN-401, its gene therapy candidate for Rett syndrome. Both leaders bring extensive experience in rare neurological diseases, strategic transactions and commercialization as Neurogene advances its registrational Embolden trial and prepares for potential future commercialization.
Neurogene Inc. calls a virtual-only 2026 annual meeting on June 3, 2026 at 9:00 a.m. Eastern to elect two Class III directors, hold several advisory votes on executive pay and its frequency, and ratify Deloitte & Touche as auditor for 2026.
Stockholders of record on April 7, 2026, when 15,615,786 common shares were outstanding, may vote online, by phone, mail, or during the live webcast. The proxy details a classified six‑member board, majority and supermajority voting standards, and restrictions on stockholder‑called special meetings and written consents.
The filing also discloses 2025 executive pay, including salary, cash bonuses, stock options, and restricted/performance share units, plus change‑in‑control and termination protections for key executives such as CEO Rachel McMinn, President/CFO Christine Mikail, and CMO Julie Jordan.
Neurogene Inc. President and CFO Christine Mikail Cvijic reported an open-market sale of 2,558 shares of common stock on March 26, 2026 at a weighted average price of $21.6247 per share. According to the disclosure, this sale was mandatory and executed by the company solely to cover her tax withholding obligation arising from the partial vesting of a Restricted Stock Unit (RSU) award, with no election made by her.
After this transaction, she directly holds 103,240 shares, which include multiple unvested RSU grants: 10,635 RSUs granted on March 13, 2024 that vest on March 13, 2027; 13,533 RSUs granted on March 26, 2025 that vest in equal annual installments on March 26, 2027 and March 26, 2028; and 22,000 RSUs granted on February 20, 2026 that vest in equal annual installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 19,200 are held jointly with her spouse.
Neurogene Inc. director and CEO Rachel McMinn reported an automatic sale of common stock tied to RSU vesting. On March 26, 2026, 3,352 shares of Neurogene common stock were sold at a weighted average price of $22.0749 per share to cover tax withholding from a partially vested Restricted Stock Unit award. The award agreement required the company to sell enough shares to satisfy tax obligations, with no election by McMinn, making this a mechanistic tax-related sale rather than a discretionary open-market trade. After the transaction, she directly held 1,344,307 shares of common stock, along with additional restricted stock units scheduled to vest between February 2027 and February 2029.
Neurogene Inc. Chief Medical Officer Julie Jordan reported an open-market sale of 828 shares of Common Stock at a weighted average price of $21.8932 per share. According to the disclosure, this sale was mandatory and executed solely to cover tax withholding arising from a partially vested restricted stock unit (RSU).
After this transaction, Jordan reports holding 12,472 shares, including 5,600 RSUs that vest in equal annual installments on March 26, 2027 and March 26, 2028, and 4,900 RSUs that vest in equal annual installments on February 20, 2027, February 20, 2028 and February 20, 2029, all subject to continued service.
Neurogene Inc. is a clinical-stage biotech focused on genetic medicines for severe neurological diseases, led by NGN-401, a gene therapy for Rett syndrome using its proprietary EXACT transgene regulation platform and in-house AAV manufacturing.
The Phase 3 Embolden trial of NGN-401 is fully enrolled, with over half of participants dosed, and prior Phase 1/2 data showed functional gains and generally well-tolerated safety at the 1E15 vg dose. NGN-401 has received Breakthrough Therapy, RMAT and PRIME designations and was selected for the FDA’s START pilot program.
Neurogene remains pre-revenue and deeply loss-making, reporting a net loss of $90.4 million in 2025 versus $75.1 million in 2024, with an accumulated deficit of $352.6 million as of December 31, 2025. Cash, cash equivalents and short-term investments totaled $269.0 million, and management expects to need substantial additional capital as it advances clinical programs and scales its 42,000-square-foot Houston cGMP facility. As of March 18, 2026, the company had 15,574,293 common shares outstanding.
Neurogene Inc. reported a full year 2025 net loss of $90.4 million, widening from $75.1 million in 2024, as it increased investment in its Rett syndrome gene therapy program NGN-401.
Research and development expenses rose to $75.0 million from $60.9 million, and general and administrative expenses increased to $28.3 million from $22.6 million, mainly due to higher clinical trial and employee-related costs. The company ended 2025 with $269.0 million in cash, cash equivalents and short-term investments, which it expects to fund operations through the first quarter of 2028.
Clinically, Neurogene fully enrolled its Embolden registrational trial for NGN-401 in Rett syndrome, with more than half of participants dosed and dosing completion targeted for the second quarter of 2026. Interim Phase 1/2 data at the 1E15 vg dose showed multidomain, durable functional gains across motor and communication domains, with NGN-401 generally well-tolerated and no cases of hemophagocytic lymphohistiocytosis.
NGN-401 received FDA Breakthrough Therapy designation based on interim Phase 1/2 data, and the FDA confirmed commercial manufacturing scale will match clinical scale, avoiding comparability studies. Neurogene plans to begin a Process Performance Qualification campaign and present updated Phase 1/2 data, including at least 12 months of follow-up for all 10 participants, in mid-2026, while continuing early commercial-readiness and payor engagement activities.
Neurogene Inc. Chief Scientific Officer Stuart Cobb reported selling 6,797 shares of common stock in three open-market transactions on March 13, 2026. The sales occurred at prices reported as weighted averages of $20.41, $21.34, and $22.08, with detailed ranges noted in the disclosure.
The filing states these trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on February 6, 2025. After these transactions, Cobb directly holds 30,497 shares, which include restricted stock units scheduled to vest between 2026 and 2029, subject to continued service.